Health Condition 1: null- DIABETES MELLITUS
Conditions
Interventions
Intervention1: Bevacizumab,: inj Bevacizumab
1.25mg 3 doses monthly and
given by intravitreal routein a duration of 3 months.
Control Intervention1: triamcinolone: inj Triamcinolone single dose
4 mg
Sponsors
Nethradhama Superspeciality Eye Hospita
Eligibility
Inclusion criteria
Inclusion criteria: • All Patients with clinically significant macular oedema (according to ETDRS study) with systemic diabetis mellitus of > 3 months duration. • Patients were required to have a baseline CRT of at least 300 um and BCVA of 20/25 to 20/400 Snellen equivalent in the study eye. • Patients with HbA1c controlled at less than 8.0% at the beginning and during the study duration.
Exclusion criteria
Exclusion criteria: Patients with bilateral macular oedema, with retinal thickness difference between two eyes of >100um. Patient with history of • Macular Laser Photocoagulation • Intravitreal Injection Therapy • Active Proliferative Diabetic Retinopathy (PDRP) With Necessity Of Panretinal Laser Treatment • Panretinal Laser Treatment Within The Past 3 Months • Previous vitreous surgery • IHD & CVA
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare retinal morphology and function following intravitreal injections of bevacizumab or triamcinolone in patients with diabetic macular edemaTimepoint: 1 year | — |
Secondary
| Measure | Time frame |
|---|---|
| â?¢ Paired eyes of each patient is used to avoid possible bias of systemic factors glycemic control, blood pressure and nephropathy. Retreatment rate in both groups.Timepoint: 1 year | — |
Countries
India
Contacts
Public ContactDr CHANDRA KUMAR
Nethradhama Superspeciality Eye Hospita
Outcome results
None listed